Epidemiological and molecular biological study of therapy-related myeloid neoplasms
Project/Area Number |
16K09843
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Hematology
|
Research Institution | Kanazawa University |
Principal Investigator |
OHTAKE SHIGEKI 金沢大学, その他部局等, その他 (00160523)
|
Co-Investigator(Kenkyū-buntansha) |
片桐 孝和 金沢大学, 保健学系, 助教 (60621159)
|
Research Collaborator |
MIYAZAKI yasushi
KIYOI hitoshi
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 治療関連骨髄性腫瘍 / 急性骨髄性白血病 / 骨髄異形成症候群 / 染色体異常 / キメラ遺伝子解析 / AML / MDS / CMMoL / 治療関連骨髄性腫瘍(t-MN) / 染色体核型 / 疫学的検討 / 癌 / 白血病 |
Outline of Final Research Achievements |
We analyzed 3 databases of acute myeloid leukemia (AML) that was registered from all of the country. Frequency of therapy-related myeloid neoplasms(t-MN) was between 5.1 and 8.1%. Patients with t-MN were older than patients with de novo AML, and sex difference was not observed. Adverse cytogenetics were observed most frequently in patients with t-MN. Five years survival rate in patients with t-MN was significantly inferior to patients with de novo AML and was less than 20%. Survival probability in patients with t-MN might improve if they could receive intensive treatment.
|
Academic Significance and Societal Importance of the Research Achievements |
化学療法や放射線療法後に出現する治療関連骨髄性腫瘍は近年増加しており、がん患者の予後が改善することに伴って注目されている。治療関連骨髄性腫瘍の疫学的特徴を10,000例以上の多数の症例が登録されたデータベースを用いて明らかにした。
|
Report
(4 results)
Research Products
(10 results)
-
[Journal Article] Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.2019
Author(s)
Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kitamura K, Sakaida E, Takeshita A, Suzushima H, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H
-
Journal Title
Ann Hematol
Volume: 98
Issue: 1
Pages: 83-91
DOI
NAID
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.2019
Author(s)
Takeshita A, Asou N, Atsuta Y, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Furumaki H, Obata Y, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y
-
Journal Title
Leukemia
Volume: 33
Issue: 2
Pages: 358-370
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols.2018
Author(s)
Kato H, Fujita H, Akiyama N, Kimura SI, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Minamiguchi H, Miyatake J, Handa H, Kanda Y, Yoshida M, Miyawaki S, Ohtake S, Naoe T, Kiyoi H, Matsumura I, Miyazaki Y
-
Journal Title
Support Care Cancer
Volume: 26
Issue: 12
Pages: 4187-4198
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
[Presentation] Prospective Evaluation of Prognostic Relevance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: Results from the JALSG CBF-AML209-KIT Study.2018
Author(s)
Kawashima N, Ishikawa Y, Atsuta Y, Sugiura I, Sawa M, Dobashi N, Yokoyama H, Doki N, Tomita A, Kiguchi T, Koh S, Kanamori H, Iriyama N, Kohno A, Moriuchi Y, Asada N, Hirano D, Togitani K, Sakura T, Hagihara M, Tomikawa T, Yokoyama Y, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T and Kiyoi H
Organizer
60th American Society of Hematology Annual Meeting
Related Report
Int'l Joint Research
-
[Presentation] Tamibarotene As Maintenance Therapy for Acute Promyelocytic Leukemia Improved Long Term Relapse-Free Survival: 7-Year Results from a Randomized Controlled Trial, JALSG-APL204.2017
Author(s)
Takeshita A, Asou N, Yanada M, Sakura T, Ueda Y, Sawa M, Dobashi N, Onizuka M, Taniguchi Y, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Furumaki H, Fujita H, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Atsuta Y, Matsumura I, Naoe T and Miyazaki Y
Organizer
第59回米国血液学会
Related Report
Int'l Joint Research